Back to discover
Disease

Acquired Immunodeficiency Syndrome

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHAcquired Immunodeficiency Syndrome
3
Publications
24
Clinical trials
1
Related conditions
8
Associated genes
1
Related proteins
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.

Research2023-04-24Frontiers in immunology

Reflections on 40 Years of AIDS.

Research2021-06-01Emerging infectious diseases

Diarrhea in developed and developing countries: magnitude, special settings, and etiologies.

Research1990-01-01Reviews of infectious diseases

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q2 2029.
Upcoming Milestones
Clinical Milestones7View
Results expected 2
Recently completed 1
Other updates 4
Activity timeline7

Clinical trials

11 sponsors · 0 new · 0 completed in the last 12 months (net -4)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Implementation for Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals Using Novel Regimen of Isoniazid/Rifapentine Daily (4 Weeks) Compared to Isoniazid/Rifapentine Weekly (12 Weeks)

Phase 3 · Active, not recruiting · The HIV Netherlands Australia Thailand Research Collaboration

A Phase 2/3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

Phase 2/3 · Active, not recruiting · Gilead Sciences

A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed

Phase 3 · Active, not recruiting · ViiV Healthcare

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants

Phase 3 · Active, not recruiting · Merck Sharp & Dohme LLC

A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

Phase 3 · Active, not recruiting · Gilead Sciences

A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Phase 3 · Active, not recruiting · Merck Sharp & Dohme LLC
Recently completed

Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone

Phase 4 · Completed · Boehringer Ingelheim

Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir)

Phase 3 · Completed · Boehringer Ingelheim

An Open-label, Non-randomized, Single-arm Study, to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma High Density Lipoproteins Concentration in HIV+ Subjects Treated With VIRAMUNE® Tablets

Phase 4 · Completed · Boehringer Ingelheim

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

Phase 3 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo

Phase 3 · Completed · Pharmacia

A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis

Phase 3 · Completed · SmithKline Beecham

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
1990–2023
Most influential

Diarrhea in developed and developing countries: magnitude, special settings, and etiologies.

Reviews of infectious diseases · 1990 · 205 cites

Reflections on 40 Years of AIDS.

Emerging infectious diseases · 2021 · 61 cites

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.

Frontiers in immunology · 2023 · 37 cites
Recent publications

mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.

Frontiers in immunology · 2023 · 37 cites

Reflections on 40 Years of AIDS.

Emerging infectious diseases · 2021 · 61 cites

Diarrhea in developed and developing countries: magnitude, special settings, and etiologies.

Reviews of infectious diseases · 1990 · 205 cites
Major themes8
  • Acquired Immunodeficiency Syndrome2
  • COVID-192
  • Communicable Diseases1
  • Disease Outbreaks1
  • Hemorrhagic Fever, Ebola1
  • HIV Infections1
  • Malaria1
  • Tuberculosis1
Leading journals3
  • Emerging infectious diseases1
  • Frontiers in immunology1
  • Reviews of infectious diseases1
Leading researchers8
  • Bettencourt PJG1
  • Crane J1
  • Curran JW1
  • De Cock KM1
  • Guerrant RL1
  • Hughes JM1
  • Jaffe HW1
  • Lima NL1
Affiliations (unnormalised)2
  • Center for Interdisciplinary Research in Health1
  • University of Virginia School of Medicine1

Associated genes

8 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

CCR50.28CCL3L30.07SERPINA90.03CLEC9A0.02ACSM40.02ENTPD40.01ZNF1750.01DEFB1270.00

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

C-C chemokine receptor type 5via CCR50.28

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

COVID-192

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.

Identifiers
MeSHAcquired Immunodeficiency Syndrome
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.